Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
TVTX
Stock Latest News
The Fly
Nvidia reports Q2 beat, Snowflake posts ‘beat and raise’: Morning Buzz
20h ago
F
DG
Premium
The Fly
Ligand price target raised to $206 from $157 at H.C. Wainwright
22h ago
LGND
TVTX
Premium
The Fly
Travere Therapeutics price target raised to $47 from $30 at H.C. Wainwright
1d ago
TVTX
Premium
Ratings
Buy Rating Affirmed for Travere Therapeutics Amid Positive FDA Changes for Filspari
1d ago
TVTX
Premium
The Fly
Travere Therapeutics’ filspari granted FDA approval for REMS labeling
2d ago
TVTX
Premium
Ratings
Strategic Positioning and Growth Potential Drive Buy Rating for Travere Therapeutics
11d ago
TVTX
Premium
Ratings
Positive Growth Outlook for Travere Therapeutics Driven by Filspari’s Market Potential and Strategic Initiatives
18d ago
TVTX
Premium
The Fly
Travere Therapeutics price target raised to $34 from $32 at Citi
19d ago
TVTX
Premium
Ratings
Strong Sales Performance and Market Expansion Potential Drive Buy Rating for Travere Therapeutics
21d ago
TVTX
Premium
Company Announcements
Travere Therapeutics Earnings Call Highlights FILSPARI Success
21d ago
TVTX
Premium
The Fly
Travere Therapeutics price target raised to $31 from $30 at Scotiabank
22d ago
TVTX
Premium
The Fly
Travere Therapeutics price target raised to $32 from $30 at Wedbush
22d ago
TVTX
Premium
Company Announcements
Travere Therapeutics Reports Strong Q2 2025 Growth
22d ago
TVTX
Premium
Ratings
Sustained Growth and Strategic Milestones Drive Buy Rating for Travere Therapeutics
23d ago
TVTX
Premium
The Fly
Travere Therapeutics reports Q2 EPS (14c), consensus (1c)
23d ago
TVTX
Premium
Ratings
Buy Rating for Travere Therapeutics: Strong Market Position and Growth Potential with Filspari and FSGS Expansion
2M ago
TVTX
Premium
Ratings
Buy Rating on Travere Therapeutics: Undervaluation Amidst IgAN and FSGS Opportunities
3M ago
TVTX
Premium
The Fly
Travere Therapeutics asumed with a Buy at H.C. Wainwright
3M ago
TVTX
Premium
Ratings
Buy Rating for Travere Therapeutics: Anticipated FDA Approval and Strategic Developments Signal Significant Upside Potential
3M ago
TVTX
Premium
The Fly
Citi trims Travere target, opens ‘upside 90-day catalyst watch’
3M ago
TVTX
Premium
The Fly
Cito trims Travere target, opens ‘upside 90-day catalyst watch’
3M ago
TVTX
Premium
Ratings
Buy Rating for Travere Therapeutics Amid Filspari’s FDA Review and Market Potential
3M ago
TVTX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
